Compare ARDX & WLFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARDX | WLFC |
|---|---|---|
| Founded | 2007 | 1985 |
| Country | United States | United States |
| Employees | N/A | 475 |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2014 | 1997 |
| Metric | ARDX | WLFC |
|---|---|---|
| Price | $6.21 | $201.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | $15.14 | ★ $160.00 |
| AVG Volume (30 Days) | ★ 3.0M | 44.9K |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 0.80% |
| EPS Growth | N/A | ★ 146.23 |
| EPS | N/A | ★ 13.89 |
| Revenue | $2,607,000.00 | ★ $569,223,000.00 |
| Revenue This Year | $37.75 | $2.75 |
| Revenue Next Year | $34.24 | $7.35 |
| P/E Ratio | ★ N/A | $14.47 |
| Revenue Growth | N/A | ★ 36.00 |
| 52 Week Low | $3.50 | $114.01 |
| 52 Week High | $8.40 | $207.05 |
| Indicator | ARDX | WLFC |
|---|---|---|
| Relative Strength Index (RSI) | 56.13 | 69.52 |
| Support Level | $5.49 | $192.00 |
| Resistance Level | $6.23 | $206.77 |
| Average True Range (ATR) | 0.24 | 6.70 |
| MACD | 0.10 | 4.14 |
| Stochastic Oscillator | 94.53 | 99.39 |
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Willis Lease Finance Corp, with its subsidiaries, is a lessor and servicer of commercial aircraft and aircraft engines. The company has two reportable business segments, which include Leasing and Related Operations and Spare Parts Sales. A majority of its revenue is generated from the Leasing and Related Operations segment, which involves acquiring and leasing, under operating leases, commercial aircraft, aircraft engines, and other aircraft equipment and the selective purchase and resale of commercial aircraft engines, aircraft equipment, and other related businesses. Geographically, the company derives maximum Lease rent revenue from the United States, followed by Europe, Asia-Pacific (excluding India), India, South America, Canada, Central America, and the Middle East.